# US 7,608,587 B2 · Exendin 4 polypeptide fragment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,587 B2
- Document ID: US7608587B2
- Status: Granted
- Kind: B2
- Application number: 11/497,075
- Filed: 2006-08-01
- Published: 2007-02-15
- Granted: 2009-10-27
- Earliest claimed: 2005-06-29
- Assignees: Changzhou Pharmaceutical Factory
- Inventors: Xiaopeng Ma; Bing Wang; Shaoqi Xi
- Web page: https://patentgrep.com/patent/US7608587B2

## CPC

- C07K 14/57563: {Vasoactive intestinal peptide [VIP]; Related peptides}
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to an Exendin 4 polypeptide fragment, which has hypoglycemic activity, and can be used for the treatment of type II diabetes mellitus. The polypeptide sequence described herein is HGEGTX1TSDLSKQX2EEEAVX3LFIEWLKNGX4PX5, where X1 represents Phe or Tyr, X2 represents Met, Ile or Leu, X3 represents Lys, X4 represents Gly or deletion, X5 represents Arg or deletion. Additionally, the present invention relates to a method for the Exendin 4 polypeptide fragment preparation.

## Claims

### Claim 1

A polypeptide, pharmaceutically acceptable salt, or ester thereof, comprising the sequence represented by SEQ ID 73.

### Claim 2 (depends on 1)

The polypeptide of claim 1 comprising the sequence represented by SEQ ID 74.

### Claim 3 (depends on 1)

The polypeptide of claim 1 comprising the sequence represented by SEQ ID 75.

### Claim 4 (depends on 1)

The polypeptide of claim 1 comprising the sequence represented by SEQ ID 76.

### Claim 5 (depends on 1)

The polypeptide of claim 1, comprising the sequence represented by SEQ ID 4.

### Claim 6 (depends on 1, 2, 3, 4, 5)

A pharmaceutical composition containing one or more of polypeptides stated in any one of claims 1-5.

### Claim 7 (depends on 6)

The pharmaceutical composition of claim 6, further containing pharmaceutically acceptable thinners, excipients or carriers.

### Claim 8 (depends on 7)

The pharmaceutical composition of claim 7, wherein the carriers described refer to one or more of ethanol, glycerol, or water.

### Claim 9 (depends on 1, 2, 3, 4, 5)

A method for treating diabetes mellitus, the method comprising administering one or several kinds of polypeptides stated in any one of claims 1-5.

### Claim 10 (depends on 9)

The method of claim 9, wherein diabetes mellitus is type II diabetes mellitus.